Anaemia correction in predialysis elderly patients: influence of the antihypertensive therapy on darbepoietin dose
Anaemia and hypertension are common in patients with chronic renal insufficiency. The correction of anaemia with erythropoiesis stimulating agents (ESA) can improve survival and decrease the decline of renal function. Angiotensin converting-enzyme inhibitors (ACEI) and angiotensin II receptor blockers (AIIRA) can also slow the progression of renal failure, but the blockade of the renin-angiotensin system can worsen anaemia. The aim of our study was to assess the impact of antihypertensive therapy (ACEI plus AIIRA) in the requirements of darbepoietin in a group of elderly predialysis patients. We included 71 patients (m = 39, f = 32), mean age of 76.3 years with a mean creatinine clearance of 17.5 ml/min. Patients were divided in two groups according to their antihypertensive therapy: G-I patients under ACEI or AIIRA therapy and G-II normotensive patients or hypertensive patients under antihypertensive drugs other than ACEI or AIIRA. The groups were compared regarding demographic, nutritional, biochemical and inflammatory parameters. We also compared the mean darbepoietin dose. In GI the mean dose of darbepoietin was higher than in GII (0.543 vs. 0.325 µg/kg/week, P = 0.032). We did not find any difference regarding other parameters analysed. We conclude that ACEI and AIIRA can increase the needs of darbepoietin in predialysis elderly patients. However, when formally indicated to treat hypertension in a specific patient, they should not be switched to another antihypertensive agent. Instead, in such cases, higher doses of ESA should be used, if necessary.
KeywordsAntihypertensive drugs Darbepoietin Predialysis
Unable to display preview. Download preview PDF.
- 1.Samiy AH (1984) Renal disease in the elderly. Med Clin North Am 67:463–480Google Scholar
- 2.Oreopoulos DG (1990) The aging kidney. Adv Perit Dial 6(Suppl):2–5Google Scholar
- 3.Raine AEG, Margreiter R, Brunner FP et al (1992) Report on management of renal failure in europe, XXII, 1991. Nephrol Dial Transplant 7(Suppl 2): 7–35Google Scholar
- 4.Annual report (2002) ESRD clinical performance measures project. Am J Kidney Dis 39(Suppl 2):S4–S98Google Scholar
- 7.Revised European Best Practice Guidelines (2004) For the management of anaemia in patients with chronic renal failure. Section II: targets for anaemia treatment. Nephrol Dial Transplant 19(Suppl 2):ii6–ii15Google Scholar
- 9.Coca A (1998) Actual blood pressure control: are we doing things right ? J Hypertens 16(Suppl 1):S45–S51Google Scholar
- 10.Juan PC, Weiliang C, Stavros L, Patrick V et al (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026–2033Google Scholar
- 11.Maschio G, Albert D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zuchelli P (1996) Angiotensin converting enzyme inhibition in progressive renal insufficiency study group. Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of renal insufficiency. N Engl J Med 334:939–945PubMedCrossRefGoogle Scholar
- 18.Gault MH, Longerich LL, Harnett JD, Wesolowski C (1992) Predicting glomerular function from adjusted serum creatinine (editorial). Nephron 62:249Google Scholar
- 22.Friedman EA (2001) Must (should) all ESRD patients be treated? In: Levinsky NG (ed) Ethics and the kidney. Oxford University Press, Oxford, pp 85–98Google Scholar
- 24.Woodhouse KW, Wynne H, Baille S et al (1988) Who are the frail elderly? Q J Med 255:505–506Google Scholar
- 25.Revised European Best Practice Guidelines (2004) For the management of anaemia in patients with chronic renal failure. Section IV: failure to respond to treatment. Nephrol Dial Transplant 19(Suppl 2):ii32–ii36Google Scholar